{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:28Z","timestamp":1787027008357,"version":"build-2736575974"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"\n Purpose<\/jats:title>\n Mirabegron is a recent addition to the management options of overactive bladder (OAB) in children. The purpose of this study was to ascertain the role of Mirabegron in the treatment algorithm of therapy-resistant OAB especially after botulinum toxin.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Case notes of all children receiving Mirabegron between July 2017 and February 2020 were reviewed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Forty one children (21 females, 20 males), mean age 12.6 [8\u201317] years old, commenced Mirabegron: 35 idiopathic OAB, 6 neuropathic OAB. The mean duration of treatment was 20.7 [3\u201345] months. In total 24 (59%) had Mirabegron after partial\/no response to anticholinergics, and 17 (41%) patients had Mirabegron subsequent to botulinum toxin A (BtA) as an exit strategy. In total 35 (85%) patients had combination therapy (Mirabegron and anticholinergics), and 6 (15%) patients had Mirabegron only. Fourteen (34%) had complete response, 17 (41%) had partial response, and 10 (24%) had no response. Side effects were reported in 7 (17%) patients with discontinuation necessitated in 3.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Mirabegron when used alone or in combination with anticholinergics resulted in complete\/partial response in 76% of anticholinergic therapy-resistant OAB. In addition to being an important step in treatment escalation after no\/partial response to anticholinergics, it has a crucial role in the exit strategy for recurring symptoms after BtA wears off.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fped.2021.801517","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:38:31Z","timestamp":1645144711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children"],"prefix":"10.3389","volume":"9","author":[{"given":"Denise Jia Yun","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/nau.22751","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society","volume":"35","author":"Austin","year":"2006","journal-title":"Neurourol Urodynam."},{"key":"B2","unstructured":"Overactive bladder in children707\n OliveriaRG\n UbirajaraBJ\n Eur Med J.32018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1442-2042.2006.01217.x","article-title":"Nocturnal enuresis and overactive bladder in children: an epidemiological study","volume":"13","author":"Kajiwara","year":"2006","journal-title":"Int J Urol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.urology.2008.06.063","article-title":"Prevalence and associated factors of overactive bladder in Korean children 5\u201313 years old: a nationwide multicenter study","volume":"73","author":"Chung","year":"2009","journal-title":"Urology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1464-410x.1998.00015.x","article-title":"An Italian epidemiological multicentre study of nocturnal enuresis","volume":"81","author":"Chiozza","year":"1998","journal-title":"Br J Urol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1542\/peds.113.2.334","article-title":"Coping, commitment, and attitude: quantifying the everyday burden of enuresis on children and their families","volume":"113","author":"Landgraf","year":"2004","journal-title":"Pediatrics."},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","article-title":"Prospective pilot study of Mirabegron in pediatric patients with overactive bladder","volume":"70","author":"Blais","year":"2016","journal-title":"Eur Urol."},{"key":"B8","unstructured":"FDA Approves New indication for Drug to Treat Neurogenic Detrusor Overactivity in Pediatric Patients2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/jcph.1107","article-title":"Cardiovascular safety of the \u03b23-adrenoceptor agonist Mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial","volume":"58","author":"White","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of Mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jpedsurg.2019.10.044","article-title":"Effectiveness and tolerability of Mirabegron in Children with overactive bladder: a retrospective pilot study","volume":"55","author":"Fryer","year":"2020","journal-title":"J of Paed Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.juro.2016.11.101","article-title":"Dual therapy for refractory overactive bladder in children: a prospective open-label study","volume":"197","author":"Morin","year":"2016","journal-title":"J Urol."},{"key":"B13","unstructured":"Mirabegron for treating symptoms of overactive bladder2013"},{"key":"B14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jpurol.2018.08.007","article-title":"Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes","volume":"15","author":"Ingham","year":"2019","journal-title":"J Pediatr Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoreceptor agonist, in patients with overactive bladder: results from a randomised european-australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.801517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:38:33Z","timestamp":1645144713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.801517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":15,"alternative-id":["10.3389\/fped.2021.801517"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.801517","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"article-number":"801517"}}